التفاصيل البيبلوغرافية
| العنوان: |
MET Exon 14 Skipping in Non-Small Cell Lung Cancer. |
| المؤلفون: |
Heist, Rebecca S., Shim, Hyo Sup, Gingipally, Shalini, Mino‐Kenudson, Mari, Le, Long, Gainor, Justin F., Zheng, Zongli, Aryee, Martin, Xia, Junfeng, Jia, Peilin, Jin, Hailing, Zhao, Zhongming, Pao, William, Engelman, Jeffrey A., Iafrate, A. John |
| المصدر: |
Oncologist; Apr2016, Vol. 21 Issue 4, p481-486, 6p, 1 Color Photograph, 4 Charts, 1 Graph |
| مصطلحات موضوعية: |
LUNG cancer diagnosis, LUNG cancer & genetics, PROTEIN kinase inhibitors, COMPUTED tomography, DYSPNEA, GENES, GENETIC techniques, LUNG cancer, GENETIC mutation, RESEARCH funding, SMOKING, TREATMENT effectiveness, DESCRIPTIVE statistics, SEQUENCE analysis, THERAPEUTICS |
| مصطلحات جغرافية: |
MASSACHUSETTS |
| مستخلص: |
Background. Non-small cell lung cancers (NSCLCs) harboring specific genetic alterations can be highly sensitive to targeted therapies. Materials and Methods. We performed a targeted rearrangement assay on 54 NSCLCs across all stages that were from patients who were never smokers and did not have driver mutations. Because MET exon 14 skipping was the most frequent alteration found, we surveyed the results for MET exon 14 skipping at Massachusetts General Hospital (MGH) since the inclusion of this alteration into our current molecular profiling panel. Results. In a cohort of 54 never-smokers with lung cancers that were wild-type for known driver mutations, MET exon 14 skipping was the mostfrequently recurring alteration, occurring in 10 cancers (19%). Clinical testing at MGH via our next-generation sequencing (NGS) and NGS-rearrangement panels showed an additional 16 cases of METexon 14 skipping, for an overall estimated frequency of 5.6%. A clinical case of a patient with MET exon 14 skipping treated with the MET inhibitor crizotinib is also described. Conclusion. MET exon 14skippingisatargetablegenealteration found in NSCLC. Patients with these alterations may respond well to MET inhibition. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder